For early-stage HER2-positive breast cancer patients, anti-HER2 targeted therapy within 6 months after surgery is the optimal strategy, and the longer the delay in starting adjuvant therapy is the worse the DFS and OS, so targeted therapy should be started as soon as possible 47, 48. This evidence concerns the gene ERBB2 and breast cancer.